FBR Upgrades Keryx Biopharma To Outperform, Sees Meaningful Auryxia Sales & Potential Label Expansion

Loading...
Loading...

FBR’s Christopher S. James upgraded the rating for Keryx Biopharmaceuticals KERX from Market Perform to Outperform, with a price target of $10.

The company reported a higher-than-expected 4Q loss per share of $0.36, due to interest expenses related to the amortization of convertible debt. Keryx Biopharma announced that the prescription volume for Auryxia [ferric citrate] grew approximately 46 percent during the quarter and was driven by growth in non-IMS channels.

Analyst Christopher James expects the company to execute the European strategy for Fexeric [ferric citrate] through a series of regional partnerships and not a Pan-European partnership. He added, “We believe 2016 will be a year of meaningful Auryxia sales and remain focused on potential label expansion.”

The readout of data from the Phase III study in iron deficiency anemia [IDA] patients is expected in early 2Q16 with a potential regulatory filing in 3Q16. The EPS estimates for the current FY and the next FY have been reduced from ($0.66) to ($0.81) and from ($0.04) and ($0.31), respectively.

Posted In: Analyst ColorLong IdeasUpgradesAnalyst RatingsTrading IdeasChristopher S. JamesFBR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...